Overview and Management of Chalazion

Authors

  • Lintang Lestari Cahya Sawitri Universitas Lampung
  • Putu Ristyaning Ayu Sangging
  • Rani Himayani

DOI:

https://doi.org/10.53089/medula.v13i4.1.687

Keywords:

chalazion, lid inflammation, Meibomian glands

Abstract

Chalazion is the most common local inflammatory condition, accounting for 13.4% of all benign eyelid lesions, caused by obstruction of the meibomian glands in the upper or lower lid, either unilaterally or bilaterally. Chalazion is a chronic granulomatous inflammatory condition of the Meibomian glands which are responsible for producing meibum which can reduce tear evaporation and facilitate lubrication of the ocular surface. This situation is often associated with acne rosacea, atopy, seborrheic, and chronic blepharitis. The lesions are inflammatory nodules that form when the products of lipid breakdown enter the surrounding tissue and trigger a granulomatous inflammatory reaction. The nodule is not more than 1 cm in size, not hyperemic, not painful when pressed, not fluctuate, and pseudoptosis. Single hard textured nodule located deep in the upper or lower lid or tarsal. Management can be done through a conservative approach, antibiotics, and surgery. Conservative medical treatments include warm compresses, eyelid massage, eyelid scrubs, and eyelid cleansing with baby shampoo. Antibiotics are generally not indicated, unless the condition is associated with severe blepharitis or blepharitis due to rosacea. Persistent lesions require surgical intervention. Smaller lesions are treated by surgical curettage and dissection. Larger lesions require more extensive excision. Good sleeping habits, regular exercise, and fresh air are essential to promote healthy skin and Meibomian glands.

Author Biographies

Putu Ristyaning Ayu Sangging

 

 

Rani Himayani

 

 

References

Soebagjo HD. Penyakit Sistem Lakrimal. Surabaya: Airlangga University Press; 2019.

Li J, Li D, Zhou N, Qi M, Lou Y, Wang Y. Effect of chalazion and its treatments on the meibomian glands: a nonrandomized, prospective observation clinical study. BMC Ophthalmology Journal. 2020;20(278):1-8.

Jordan GA, Beier K. Chalazion [internet]. Treasure Island: StatPearls Publishing; 2022 [diperbarui tanggal 1 Agustus 2022; disitasi tanggal 12 Maret 2023]. Tersedia dari: https://pubmed.ncbi.nlm.nih.gov/29763064/

Suzuki T, Dkk. Reconsidering the pathogenesis of chalazion. The Ocular Surface Journal. 2022;24(1): 31-33.

McLaughlin J, Lally SE, Shields CL. Just another chalazion?. Indian Journal Ophthalmol. 2019;67(2):195.

Hanafi Y, Oubaaz A. Leishmaniasis of the eyelid masquerading as a chalazion: Case report. Journal Fr Ophtalmol. 2018;41(1):31-33.

Elsayed MA, Kahtani SA. Chalazion Management: Evidence and Questions. Ophthalmic Pearls. 2015;1(1):37-39.

Wu AY, Gervasio KA, Gergoudis KN, Wei C, Oestreicher JH, Harvey JT. Conservative therapy for chalazia: is it really effective? Acta Ophthalmol. 2018;96(4):503-509.

Gallenga CE, Mura M, Gallenga PE. Suggestions on gut-eye cross-talk: about the chalazion. Int Journal Ophthalmol. 2022;15(9):1-3.

Aycinena AR, Achiron A, Paul M, Burgansky-Eliash Z. Incision and Curretage Versus Steroid Injection for the Treatment of Chalazia: A Meta-Analysis. Ophthalmic Plast Reconstr Surg. 2016;32(3):220-224.

Published

2023-05-31

How to Cite

Sawitri, L. L. C., Ayu Sangging, P. R., & Himayani, R. (2023). Overview and Management of Chalazion. Medical Profession Journal of Lampung, 13(4.1), 119-123. https://doi.org/10.53089/medula.v13i4.1.687

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 > >>